2016
The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus
Durning SP, Preston-Hurlburt P, Clark PR, Xu D, Herold KC, Group T. The Receptor for Advanced Glycation Endproducts Drives T Cell Survival and Inflammation in Type 1 Diabetes Mellitus. The Journal Of Immunology 2016, 197: 3076-3085. PMID: 27655844, PMCID: PMC5101164, DOI: 10.4049/jimmunol.1600197.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAsymptomatic DiseasesCD8-Positive T-LymphocytesCell SurvivalCells, CulturedChildDiabetes Mellitus, Type 1Disease ProgressionFemaleGene Expression ProfilingHumansImmunologic MemoryInflammationLymphocyte ActivationMaleReceptor for Advanced Glycation End ProductsRiskSignal TransductionUp-RegulationYoung AdultConceptsDamage-associated molecular patternsT cellsRAGE expressionT1D patientsInflammatory functionsRisk relativesCell activationHigh mobility group box 1Mobility group box 1Advanced glycated endproductsChronic autoimmune responseMolecular patternsEffector memory cellsHealthy control subjectsExpression of RAGEGroup box 1Type 1 diabetesAdvanced glycation endproductsT cell survivalAutoimmune responseAutoimmune diseasesControl subjectsDisease onsetRisk subjectsCell injury
2012
RAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses
Akirav EM, Preston-Hurlburt P, Garyu J, Henegariu O, Clynes R, Schmidt AM, Herold KC. RAGE Expression in Human T Cells: A Link between Environmental Factors and Adaptive Immune Responses. PLOS ONE 2012, 7: e34698. PMID: 22509345, PMCID: PMC3324532, DOI: 10.1371/journal.pone.0034698.Peer-Reviewed Original ResearchConceptsHuman immune responseT cellsImmune responseHuman T cellsRAGE expressionAntigen-specific T cellsAdaptive human immune responsesAdaptive immune cellsSpecific T cellsHealthy control subjectsAdaptive immune responsesExpression of RAGELevels of RAGEInnate immune responseAdvanced glycation endproductsActivated T cellsT cell activationIL-17AGlucose controlControl subjectsIL-5Immune cellsGlycation endproductsCell activationPatients